Myriad Genetics Obtains Additional Insurance Coverage for Prostate Cancer for MyChoice Diagnostic System®
NQ Score
78/100
N1 Content Completeness
9
AI Summary (NQ-processed)
Myriad Genetics announced that its MyChoice Diagnostic System has received additional health insurance coverage in Japan for prostate cancer as a companion diagnostic for Lynparza (olaparib), starting April 1, 2026.